Yesterday Critical Metals (CRTM), operator of Molulu copper/cobalt project in the Democratic Republic of Congo, provided an update on the delivery of ore to the buyer OM Metals SARL.
CRTM said the outcomes from its 24-drill-hole campaign have been tremendously encouraging, revealing high-grade copper mineralization that underscores the remarkable promise of the Molulu project. As it prepares for the next drilling phase in Q1 2024, extending into Phase 3, its goal is to deepen its understanding of the mineralization’s grade, mineralogy, thickness, and spread. This will be crucial in fulfilling off-take commitments and driving sustainable growth.
Comment: It may be said that there has been an autumn disconnect between the share price of CRTM and what is happening operationally at CRTM. Presumably, the run up to next year’s drilling will correct the valuation gap.
Chill Brands Group (CHLL), the consumer packaged-goods distribution company, announced the sale of its Chill ZERO nicotine-free vapour products into a top five UK supermarket. The Company has received a substantial initial purchase order which will see the listing of its Chill ZERO products in 1,500 of the leading supermarket chain’s UK stores. Chill ZERO products will enter these stores during Q1 2024. CHLL said it was thrilled and immensely proud to announce that it has reached agreement to sell its Chill ZERO vape products into a major UK supermarket. This milestone not only signifies a major leap forward for Chill Brands in terms of revenues, but also serves as a resounding validation of its product’s appeal and the strength of its brand.
Comment: CHLL continues to roar in terms of getting distribution, one would imagine that its products will be on every street corner imminently. It is now all about sales.
Belluscura (BELL), a medical device developer focused on lightweight and portable oxygen enrichment technology, announced that it has received approval from the National Medical Products Administration (NMPA) to distribute the X-PLOR® portable oxygen concentrator (POC) in China. BELL said it was delighted to have received approval in China which has taken over approximately 10 months. This enables it to launch sales into China with immediate effect. With its arrangement with InnoMax in place, it was confident that it can now deliver on the significant potential for its products in this large and growing market.
Comment: BELL cracking the China market is clearly a big win, especially given that it was (possibly) the home of Covid, and the smoking centre of the world.
Poolbeg Pharma (POLB), a biopharmaceutical company, announced the positive outputs from the lab-based analysis and successful prioritisation of the Respiratory Syncytial Virus drug targets and treatments identified as part of its artificial intelligence led programme. POLB said the positive outputs from this analysis, and the successful prioritisation of its RSV drug candidates, is a testament to the power of its AI-led drug discovery programme. As it engages in partnering discussions, these results position Poolbeg as a key player in the evolving landscape of AI-driven drug discovery.
Comment: The market is yet to appreciate the AI backed work that POLB is delivering, something which should perhaps become more apparent once the company offers news on partners.
RUA Life Sciences (RUA), the holding company of a group of medical device businesses focused on the exploitation of the world’s leading long-term implantable biostable polymer (Elast-Eon™), updated on recent developments of the RUA leaflet composite. RUA said combining RUA’s expertise in implantable textile materials with the clinically proven properties of ElastEon has created a novel material that appears to meet the key properties required of heart valve leaflets and it is pleasing that the business is now transitioning from a R&D phase into early stages of commercialisation.
Comment: There has been quite a volte face in shares of RUA, perhaps even more than the stock price deserved. The RNS today may settle nerves, and bring back a few bargain hunters.
Filtronic (FTC), the designer and manufacturer of products for the aerospace, defence, telecoms infrastructure and space markets, announced a new contract win with a leading global provider of low earth orbit satellite communications equipment. FTC said it was delighted to continue its partnership with the leading global provider of LEO satellites and was pleased to supply production volumes of the Cerus32 SSPA module for deployment in its ground station antenna network. The customer has always valued the flexibility of the Cerus32 design, and with this new contract is keen to take advantage of the scalable form factor and the additional power our second-generation E-band product provides”.
Comment: Another day, another £4m contract at Filtronic. One can see a pattern here, and one that even the dirge like stock market in 2023 cannot fail to be impressed by.
Disclaimer & Declaration of Interest:
The information, investment views, and recommendations in this Zaks Traders Cafe interview are provided for general information purposes only. Nothing in this interview should be construed as a promotion or solicitation to buy or sell any financial product relating to any companies under discussion or referred to or to engage in or refrain from doing so or engage in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.
